Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 5/20 | 0.34 |
| ▸ | CTSD | P07339 | 2/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HK1 | P19367 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.32 |
| ▸ | TYMS | P04818 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL932757 | 0.85 | BACE1 (0.44) | BACE1CTSDBACE2ALDH1A1MAPT | |
| SCHEMBL933481 | 0.83 | BACE1 (0.39) | BACE1CTSDBACE2ALDH1A1MAPT | |
| SCHEMBL932646 | 0.80 | BACE1 (0.46) | BACE1CTSD | |
| SCHEMBL932513 | 0.78 | BACE1 (0.51) | BACE1CTSDBACE2 | |
| SCHEMBL932184 | 0.78 | BACE1 (0.48) | BACE1CTSDBACE2 | |
| SCHEMBL947178 | 0.75 | CTSD (0.37) | BACE1CTSDBACE2ALDH1A1MAPT | |
| SCHEMBL932215 | 0.74 | BACE1 (0.41) | BACE1CTSDBACE2 | |
| SCHEMBL932046 | 0.69 | BACE1 (0.60) | BACE1CTSDBACE2 | |
| SCHEMBL931863 | 0.68 | BACE1 (0.46) | BACE1CTSDMAPT | |
| SCHEMBL933410 | 0.67 | BACE1 (0.66) | BACE1CTSDBACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011002407-A1 | NOVEL COMPOUNDS FOR TREATMENT OF NEURODEGENERATION ASSOCIATED WITH DISEASES, SUCH AS ALZHEIMER'S DISEASE OR DEMENTIA | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011002407-A1 | NOVEL COMPOUNDS FOR TREATMENT OF NEURODEGENERATION ASSOCIATED WITH DISEASES, SUCH AS ALZHEIMER'S DISEASE OR DEMENTIA | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | WO | disclosed |